Summit Clinical Research

09/16/2026

September is World Alzheimer's Month, and one number stands out. According to Alzheimer's Disease International, about 75% of people living with dementia worldwide have never been diagnosed. That means millions of families are going without answers, support, and the chance to plan ahead.

Finding it early matters. A diagnosis gives people more time to make decisions, get care, and look into options like clinical research. If you or someone you love has noticed changes in memory, a memory screening is a simple place to start.

Schedule your no-cost memory screening today:
https://www.pinnacleresearch.com/memory-screening/

08/06/2026

Liver and metabolic disease is often silent in its early stages. It builds gradually, over years, without symptoms to signal that anything is wrong.

The habits that protect against it work the same way. No single day makes the difference. The accumulation does.

Thirty minutes of movement. Water ahead of sugary drinks. A slightly earlier bedtime. A little less processed food on the plate.

Summit Clinical Research studies metabolic and liver disease because everyday habits, while meaningful, are not enough for every patient. Disease progresses in people who are doing everything asked of them. That is precisely why research into new treatments matters — and why prevention and treatment are better understood as the same effort approached from two directions.

07/31/2026

National Wellness Month starts tomorrow — so here's the number we want on your radar before August even begins: 1 in 3 U.S. adults has prediabetes, and most have no idea. It usually comes with zero symptoms.

The good news? Caught early, prediabetes can often be slowed or even reversed. Three numbers tell most of the story — fasting glucose, A1C, and BMI — and one quick lab visit covers them all.
Consider this your head start. Make August the month you know your numbers.

07/29/2026

Our Pinnacle Clinical Research Network team is bringing the latest in hepatology to San Antonio. 🍽️ Best of EASL 2026 translates this year's biggest advances in MASH/MASLD and cirrhosis management into clinical practice — featuring Dr. Naim Alkhouri (FAASLD, DABOM) and Dr. Winston Dunn (FAASLD). Aug 17 · Myron's Prime Steakhouse. If you're in the area, register below!

Join us for Best of EASL 2026 🍽️ An evening of the latest hepatology advances — and how they translate into clinical practice. Featuring Dr. Naim Alkhouri (FAASLD, DABOM) and Dr. Winston Dunn (FAASLD), with key findings from EASL 2026, emerging MASH/MASLD therapies, and advances in cirrhosis management.

📅 Monday, Aug 17 · 5:30–8:30 PM
📍 Myron's Prime Steakhouse, San Antonio.

Register now — QR below.

07/22/2026

We're proud to share the publication of a new manuscript supported by our Summit Ascend team highlighting the 12-week Phase 2 results evaluating DD01, a dual GLP-1 and glucagon receptor agonist for MASLD and MASH.

Congratulations to Mazen Noureddin, MD, MHSc, FAASLD, Winston Dunn, and the entire author team on this important publication. We'd also like to recognize the contributions of Beth Brombosz, PhD, our lead medical writer, whose expertise supported the preparation and development of the manuscript.

Additionally, this work was supported by several key members of our broader Summit team, including Rashmee Patil, MD and Dimple Desai, MD, MPH, FAAFP, DABOM, CPI, who are listed as co-authors on this important work.

A special thank you to the Neuraly Inc. team—particularly Dennis To, PhD, Adam C. Bell, PhD, RAC, Jaehee Shin, Daniel Lee, Yen-Huei Lin, and Seulki Lee—for their collaboration and partnership throughout this project.

This publication highlights the value of collaborative scientific partnerships in advancing therapies for patients with chronic liver disease while helping generate evidence that informs future clinical development and patient care.

Read the full publication below:
https://www.thelancet.com/journals/langas/article/PIIS2468-1253(26)00130-5/abstract

AstraZeneca US Eli Lilly and Company

07/09/2026

Not all clinical research sites are the same.

Summit focuses on the conditions that matter most — MASH, obesity, Alzheimer's, and cardiometabolic disease — so our physicians bring deep, specialized expertise to every visit, not a little bit of everything.

With 115+ sites in 8 countries, world-class research is closer than you think.

Clinical Research. Elevated.

07/08/2026

Our Pinnacle team will be in London for AAIC!

Check out the post below
⬇️⬇️⬇️

Big news - the Pinnacle team is heading to London for the Alzheimer's Association International Conference (AAIC) 2026! 🇬🇧🧠
Join us July 12–15 as researchers, clinicians, and industry leaders from around the world come together to share the latest breakthroughs in Alzheimer's and dementia research. If you'll be at AAIC, we'd love to connect - stop by and say hello!

07/02/2026

In observance of Independence Day, our offices will be closed on Friday, July 3rd. 🇺🇸 We hope you enjoy a wonderful holiday weekend with family and friends, and we'll be back to normal hours on Monday, July 6th. Happy 4th!

06/27/2026

That's a wrap on SOLAR 2026!

As the conference comes to a close, we're grateful for the opportunity to connect with so many dedicated clinicians, researchers, investigators, sponsors, and industry partners who are advancing the future of liver disease research.

Over the past few days, we've enjoyed insightful discussions on MASLD, MASH, obesity, metabolic health, noninvasive liver assessment, and the latest innovations in clinical research. The collaboration and knowledge shared throughout the conference continue to highlight the importance of working together to improve patient care and accelerate scientific progress.

Thank you to everyone who stopped by to connect with our team. We look forward to continuing these conversations and building on the relationships formed in San Juan.

Safe travels, and we'll see you at the next conference!

Clinical Research. Elevated.

06/26/2026

Day 2 at SOLAR 2026!

The conversations continue as experts from across the clinical research community come together to share the latest advances in MASLD, MASH, obesity, metabolic health, and liver disease.

We're proud to be a sponsor of SOLAR 2026 and to support a conference that fosters collaboration, innovation, and scientific exchange. Events like these provide an invaluable opportunity to connect with investigators, clinicians, and industry partners who are working to advance liver disease research and improve patient outcomes.

We look forward to another day of insightful discussions and meaningful connections in San Juan.